Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 3,000 Shares

Key Points

• Adam Laponis, CFO of Twist Bioscience, sold 3,000 shares at an average price of $31.15, reducing his ownership by 3.09% and retaining 94,042 shares valued at approximately $2.93 million.
• Twist Bioscience's stock has experienced a 2.2% decline, trading at $31.19, with a market capitalization of $1.88 billion.
• Analysts have mixed ratings on TWST stock, with an average rating of "Moderate Buy" and a consensus target price of $48.50.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 3,000 shares of the business's stock in a transaction dated Wednesday, October 8th. The stock was sold at an average price of $31.15, for a total transaction of $93,450.00. Following the completion of the transaction, the chief financial officer owned 94,042 shares of the company's stock, valued at $2,929,408.30. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Adam Laponis also recently made the following trade(s):

• On Thursday, October 9th, Adam Laponis sold 2,517 shares of Twist Bioscience stock. The stock was sold at an average price of $32.92, for a total transaction of $82,859.64.
• On Monday, October 6th, Adam Laponis sold 5,875 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total transaction of $189,116.25.

Twist Bioscience Stock Down 2.2%

Shares of TWST traded down $0.70 during mid-day trading on Friday, hitting $31.19. 2,506,977 shares of the company traded hands, compared to its average volume of 1,280,806. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33. The business has a 50 day moving average of $27.68 and a 200 day moving average of $32.75. The company has a market capitalization of $1.88 billion, a PE ratio of -21.51 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The firm had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on TWST shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a report on Wednesday. Barclays cut their target price on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research note on Thursday, October 2nd. Evercore ISI cut their target price on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, Cowen restated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $48.50.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after buying an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after purchasing an additional 302 shares during the period. Geneos Wealth Management Inc. acquired a new position in Twist Bioscience in the 2nd quarter worth approximately $97,000. Bayforest Capital Ltd boosted its stake in shares of Twist Bioscience by 49.3% during the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after buying an additional 1,604 shares during the period. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter valued at $201,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.